Presbia PLC (NASDAQ:LENS)‘s stock had its “buy” rating restated by research analysts at Jefferies Group LLC in a research report issued on Friday. They presently have a $10.00 price target on the medical instruments supplier’s stock, down from their prior price target of $11.00. Jefferies Group LLC’s price objective would suggest a potential upside of 91.03% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Presbia PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. ValuEngine upgraded shares of Presbia PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $11.33.

Presbia PLC (LENS) traded down 3.9543% during trading on Friday, hitting $5.0278. 1,442 shares of the stock were exchanged. The stock’s market cap is $85.25 million. Presbia PLC has a 52 week low of $2.71 and a 52 week high of $5.88. The stock has a 50 day moving average of $3.98 and a 200-day moving average of $3.98.

COPYRIGHT VIOLATION NOTICE: “Presbia PLC’s (LENS) “Buy” Rating Reiterated at Jefferies Group LLC” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/06/presbia-plcs-lens-buy-rating-reiterated-at-jefferies-group-llc.html.

An institutional investor recently raised its position in Presbia PLC stock. FMR LLC lifted its position in Presbia PLC (NASDAQ:LENS) by 0.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,568,278 shares of the medical instruments supplier’s stock after buying an additional 13,375 shares during the period. FMR LLC owned about 15.15% of Presbia PLC worth $5,856,000 as of its most recent SEC filing. 16.50% of the stock is owned by institutional investors and hedge funds.

Presbia PLC Company Profile

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.

Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.